We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Update on AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Jamie Timmons, MD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Characterization of the Enrolled Population in the Phase 3 PHOENIX Trial in Amyotrophic Lateral Sclerosis: Preliminary Results
Lead Author: Leonard van den Berg (Presenter)
Published: European Network to Cure ALS (ENCALS)
Date: July 12 - 14, 2023
Efficacy of Sodium Phenylbutyrate and Ursodoxicoltaurine Combination in Transgenic Mice Displaying Progressive Motor Neuron Degeneration Phenotype
Lead Author: Jamie Timmons (Presenter)
Published: European Network to Cure ALS (ENCALS)
Date: July 12 - 14, 2023
Effect of an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol on Long-Term Tracheostomy/Ventilation-Free Survival and Hospitalization in Amyotrophic Lateral Sclerosis: Final Results From CENTAUR
Lead Author: Janelle Schafer (Presenter)
Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Date: May 6 - 10, 2023
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 19 - 22, 2023
Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Shide Badri, MD, MPH
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Cerebrospinal Fluid Biomarker Effects and Target Engagement From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: December 3, 2022
Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Mathias Leinders, PhD
Published: Society for Neuroscience (SfN)
Date: November 12 - 16, 2022